Baxter International (NYSE: BAX) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its competitors? We will compare Baxter International to similar companies based on the strength of its profitability, dividends, earnings, valuation, analyst recommendations, risk and institutional ownership.
Earnings & Valuation
This table compares Baxter International and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Baxter International||$10.28 billion||$2.23 billion||38.74|
|Baxter International Competitors||$827.23 million||$159.49 million||36.27|
Baxter International has higher revenue and earnings than its competitors. Baxter International is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Baxter International pays an annual dividend of $0.64 per share and has a dividend yield of 1.0%. Baxter International pays out 38.8% of its earnings in the form of a dividend. As a group, “Medical Equipment, Supplies & Distribution” companies pay a dividend yield of 0.8% and pay out 37.3% of their earnings in the form of a dividend.
This is a summary of recent ratings and target prices for Baxter International and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Baxter International Competitors||174||1131||2471||89||2.64|
Baxter International currently has a consensus target price of $65.73, indicating a potential upside of 2.83%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 10.37%. Given Baxter International’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Baxter International has less favorable growth aspects than its competitors.
Volatility and Risk
Baxter International has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Baxter International’s competitors have a beta of 1.06, suggesting that their average share price is 6% more volatile than the S&P 500.
This table compares Baxter International and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Baxter International Competitors||-144.71%||-36.84%||-10.50%|
Institutional and Insider Ownership
83.6% of Baxter International shares are held by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 0.1% of Baxter International shares are held by insiders. Comparatively, 11.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Baxter International beats its competitors on 8 of the 15 factors compared.
Baxter International Company Profile
Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.
Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with our FREE daily email newsletter.